Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2009

View Archived Issues

Veltuzumab active at low doses in recurrent non-Hodgkin's lymphoma

Abeta1-15 vaccine ACI-24 shows positive safety profile in a mouse model of AD

Optimized formulation of Pronucleon peptides developed as an in vitro diagnostic tool for AD

Oral formulations of TBR-652 evaluated in healthy volunteers

ABT-089 reverses scopolamine-induced cognitive deficits in healthy volunteers

Novartis reports first results for the first half of 2009

YM-254890 shows potent bronchodilator activity in rodent models

Bristol-Myers acquires Medarex, thereby gaining rights to ipilimumab

Merck submits MAA for cladribine tablets for multiple sclerosis in Europe

Nabriva initiates phase I trial for pleuromutilin antibiotic, BC-3781

PharmaMar commences phase II Zalypsis trial in endometrial and cervical cancer

Schering-Plough files NDA for mometasone/formoterol combination for asthma

Taiho receives approval for TS-1 in Singapore

Theravance patents muscarinic receptor antagonists for the treatment of COPD and asthma

Novel PI3K inhibitors claimed by UCB for the treatment of cancer

Janssen discovers novel CB2 receptor agonists for the treatment of pain

Alcon and AstraZeneca collaborate on ophthalmic drug discovery

Takeda provides update on fixed-dose combination of alogliptin and Actos

GlaxoSmithKline completes acquisition of Stiefel

Regeneron enrolls first patient in phase III VEGF Trap-Eye program in CRVO

GSK and Enigma sign commercial partnership to develop influenza diagnostics

Peplin initiates final phase III PEP-005 gel trial in actinic keratoses

Kyowa Hakko Kirin reports results from phase III trial KW-2246 trial

AcelRx reports results from phase II study of ARX-01 Sufentanil NanoTab PCA system

Galapagos receives milestone payment under osteoporosis collaboration with Lilly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...